Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) concentration in a Veterans Affairs patient population

Journal of Clinical Lipidology

Volumn 2, Issue 6, 2008, Pages 447-452

  Alvarez, Carlos A ^a   Russell, Nicole M ^a   Edwards, Krystal L ^a   Greene, R Shane ^a   Chastain, Lisa M ^a   Weideman, Rick A ^a   Busti, Anthony J ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cholesterol; Diabetes; Fibrate; High density lipoprotein cholesterol; Thiazolidinedione

Indexed keywords

ALANINE AMINOTRANSFERASE; ANABOLIC AGENT; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; ESTROGEN; FENOFIBRATE; FISH OIL; GEMFIBROZIL; GESTAGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; THIAZIDE DIURETIC AGENT; THYROTROPIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY DISEASE; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; THYROID DISEASE; TREATMENT OUTCOME; VETERAN;

EID: 57449113248     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.10.004     Document Type: Article

References (24)

1. Cowie C.C., Rust K.F., Byrd-Holt D.D., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 29 (2006) 1263-1268
2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
3. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 suppl 1 (2008) S12-S54
4. Costa J., Borges M., David C., and Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled studies. BMJ 332 (2006) 1115-1124
5. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79 (1989) 8-15
6. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High-density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med 62 (1977) 707-714
7. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317 (1987) 1237-1245
8. Manninen V., Elo M.O., Frick M.H., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260 (1988) 641-651
9. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
10. Sacks F.M. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90 (2002) 139-143
11. Turner R.C., Millns H., Neil H.A., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ 316 (1998) 823-828
12. Ebcioglu Z., Morgan J., Carey C., and Capuzzi D. Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione. Ann Intern Med 139 (2003) e797-e798
13. Sarker A., Semble R.K., Dinneen S.F., O'Rahilly S., and Martin S.C. Severe hypo-α-lipoproteinemia during treatment with rosiglitazone. Diabetes Care 27 (2004) 2577-2580
14. Senba H., Kawano M., and Kawakami M. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone. J Athero Throm 13 (2006) 263-264
15. Gutschi L.M., Malcolm J.C., Favreau C.M., and Ooi T.C. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy. Ann Pharmacother 40 (2006) 1672-1676
16. Shetty C., Balasubramani M., Capps N., Milles J., and Ramachandran S. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. Diabetic Med 24 (2007) 94-97
17. Normen L., Frohlich J., Montaner J., et al. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 27 (2004) 2241-2242
18. Keidar S., Guttmann, Stam T., Fishman I., and Shapira C. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate. Pharmacoepi Drug Saf 16 (2007) 1192-1194
19. Crook M., Lynas J., and Wray R. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. J Clin Pathol 53 (2000) 796-797
20. Beghin L., Capps N., Duhal N., Davies J., Staels B., and Luc G. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate. Ann Clin Biochem 36 (1999) 523-525
21. Collinson P.O., Hjelm C.J., and Canepo-Anson R. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Ann Clin Biochem 33 (1996) 159-161
22. Olukoga A. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. J Clin Pathol 55 (2002) 718
23. Oleesky D., and Mir M. Paradoxical high-density lipoprotein reduction induced by fibrate therapy. Ann Clin Biochem 34 (1997) 573-574
24. Glaysher J., and Van Heyningen C. Paradoxical decrease in high density lipoprotein-cholesterol associated with statin and fenofibrate combination therapy. Br J Diabetes Vasc Dis 7 (2007) 295-297